Literature DB >> 26993416

Quantification of dose uncertainties in cumulated dose estimation compared to planned dose in prostate IMRT.

Mohamed Nassef1, Antoine Simon2, Guillaume Cazoulat2, Aurélien Duménil2, Christophe Blay3, Caroline Lafond4, Oscar Acosta2, Jacques Balosso5, Pascal Haigron2, Renaud de Crevoisier4.   

Abstract

BACKGROUND AND
PURPOSE: In prostate IMRT, the objectives were to quantify, for the bladder and the rectum: (i) the dose difference (DD) between the planned dose (PD) and the estimated cumulated dose (ECD) by deformable image registration (DIR); (ii) the dose accumulation uncertainties (DAU).
MATERIALS AND METHODS: A series of 24 patients receiving 80Gy in the prostate was used to calculate the ECDpts and the DDpts. To evaluate the DAU, a numerical phantom (ph) simulating deformations of main pelvic organs was used to calculate the ECDph using the same DIR method. A reference cumulated dose (RCDph) was calculated, based on the simulated deformations. The DAUph was defined by the differences between RCDph and ECDph.
RESULTS: For the mean dose to the bladder, the standard deviation of DDpts was 6.9Gy (18.1Gy maximum) with a DAUph of 2.7Gy. For the rectum wall, it was 2.0Gy (4.2Gy maximum) with a DAUph of 1.2Gy. Volume differences between PDpts and ECDpts, along the dose-volume histogram, ranged from -30% to +37% and -14% to +14% for the bladder and rectum, respectively. The corresponding uncertainties ranged from -23% to +7% and -4% to +7% for the bladder and rectum, respectively.
CONCLUSIONS: Large differences between planned and delivered doses to the bladder have been quantified and are higher than the uncertainties of the DIR method. For the rectum, the differences are smaller and close to the DIR uncertainties.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cumulative dose; Deformable image registration; IGRT; Phantom; Prostate

Mesh:

Year:  2016        PMID: 26993416     DOI: 10.1016/j.radonc.2016.03.007

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  6 in total

1.  Bladder surface dose modeling in prostate cancer radiotherapy: An analysis of motion-induced variations and the cumulative dose across the treatment.

Authors:  Yi Lao; Minsong Cao; Yingli Yang; Amar U Kishan; Wensha Yang; Yalin Wang; Ke Sheng
Journal:  Med Phys       Date:  2021-11-16       Impact factor: 4.071

2.  In vivo dosimetry for patients with prostate cancer to assess possible impact of bladder and rectum preparation.

Authors:  Yawo A C Fiagan; Evy Bossuyt; Daan Nevens; Piet Dirix; Frank Theys; Thierry Gevaert; Dirk Verellen
Journal:  Tech Innov Patient Support Radiat Oncol       Date:  2020-11-24

3.  Dosimetric impact of organ at risk daily variation during prostate stereotactic ablative radiotherapy.

Authors:  Lynsey Devlin; David Dodds; Azmat Sadozye; Philip McLoone; Nicholas MacLeod; Carolynn Lamb; Suzanne Currie; Stefanie Thomson; Aileen Duffton
Journal:  Br J Radiol       Date:  2020-01-30       Impact factor: 3.039

4.  MIRSIG position paper: the use of image registration and fusion algorithms in radiotherapy.

Authors:  Nicholas Lowther; Rob Louwe; Johnson Yuen; Nicholas Hardcastle; Adam Yeo; Michael Jameson
Journal:  Phys Eng Sci Med       Date:  2022-05-06

5.  Prostate external beam radiotherapy combined with high-dose-rate brachytherapy: dose-volume parameters from deformably-registered plans correlate with late gastrointestinal complications.

Authors:  Calyn R Moulton; Michael J House; Victoria Lye; Colin I Tang; Michele Krawiec; David J Joseph; James W Denham; Martin A Ebert
Journal:  Radiat Oncol       Date:  2016-10-31       Impact factor: 3.481

6.  Skin dose calculation during radiotherapy of head and neck cancer using deformable image registration of planning and mega-voltage computed tomography scans.

Authors:  Marco Branchini; Sara Broggi; Italo Dell'Oca; Giovanni Mauro Cattaneo; Riccardo Calandrino; Nadia Gisella Di Muzio; Claudio Fiorino
Journal:  Phys Imaging Radiat Oncol       Date:  2018-12-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.